drugset / Trial / NCT00239928

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

NCT00239928

Phase 2 Completed 61 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).

Timeline

Start
2005-09
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer